Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:CADLNASDAQ:GYRENASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.38+0.4%$8.02$5.11▼$10.67$1.13B1.161.32 million shs1.00 million shsCADLCandel Therapeutics$5.46-0.2%$5.60$3.79▼$14.60$273.56M-0.921.47 million shs594,799 shsGYREGyre Therapeutics$11.31+9.1%$9.02$6.11▼$19.00$1.06B1.995,976 shs48,761 shsMLYSMineralys Therapeutics$16.13-3.2%$14.44$8.24▼$18.38$1.05B-0.3479,694 shs241,828 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+0.48%+6.24%+8.88%+6.51%+49.19%CADLCandel Therapeutics-7.45%+2.43%+21.29%-55.20%-55.42%GYREGyre Therapeutics-9.04%-0.19%+23.45%-17.44%-20.84%MLYSMineralys Therapeutics+3.48%+10.26%+25.83%+74.82%+29.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals2.427 of 5 stars3.51.00.00.02.50.81.9CADLCandel Therapeutics2.0343 of 5 stars3.51.00.00.02.81.70.6GYREGyre Therapeutics0.2894 of 5 stars0.02.00.00.01.91.70.0MLYSMineralys Therapeutics2.8848 of 5 stars3.51.00.00.03.95.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5037.30% UpsideCADLCandel Therapeutics 3.00Buy$21.00284.62% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AMLYSMineralys Therapeutics 3.00Buy$38.00135.54% UpsideCurrent Analyst Ratings BreakdownLatest CADL, AUPH, GYRE, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/14/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/11/2025GYREGyre TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.002/26/2025CADLCandel TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $25.002/26/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.002/24/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.58N/AN/A$2.63 per share3.18CADLCandel Therapeutics$120K2,279.69N/AN/A$0.44 per share12.41GYREGyre Therapeutics$100.64M10.54$0.22 per share50.49$0.18 per share62.83MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.96N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)CADLCandel Therapeutics-$37.94M-$1.34N/AN/AN/AN/A-629.29%-173.39%N/AGYREGyre Therapeutics-$92.93M$0.02564.50∞N/A-84.57%-118.43%-71.97%N/AMLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%N/ALatest CADL, AUPH, GYRE, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 million3/13/2025Q4 2024CADLCandel Therapeutics-$0.23-$0.40-$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11CADLCandel TherapeuticsN/A1.181.18GYREGyre TherapeuticsN/A3.723.29MLYSMineralys TherapeuticsN/A14.0214.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%CADLCandel Therapeutics13.93%GYREGyre Therapeutics23.99%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals4.30%CADLCandel Therapeutics16.60%GYREGyre Therapeutics19.52%MLYSMineralys Therapeutics25.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableCADLCandel Therapeutics6050.10 million18.97 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableCADL, AUPH, GYRE, and MLYS HeadlinesRecent News About These CompaniesHere's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep goingMay 22 at 9:51 AM | zacks.comBalyasny Asset Management L.P. Takes $219,000 Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 21 at 3:35 AM | marketbeat.comMineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular ProtectionMay 20 at 8:00 AM | globenewswire.comTema Etfs LLC Buys New Shares in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 20 at 6:16 AM | marketbeat.comDimensional Fund Advisors LP Acquires Shares of 16,412 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 20 at 3:15 AM | marketbeat.comHere's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to BuyMay 19 at 1:06 PM | zacks.comPolar Asset Management Partners Inc. Has $1.22 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 19 at 5:52 AM | marketbeat.comSphera Funds Management LTD. Has $2.35 Million Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for MLYS Q2 Earnings?May 17, 2025 | americanbankingnews.comMineralys at BofA Securities 2025: Lorundrostat’s Hypertension PromiseMay 16, 2025 | investing.comDavid Malcom Rodman Sells 11,366 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) StockMay 16, 2025 | insidertrades.comHC Wainwright Reaffirms "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)May 15, 2025 | marketbeat.comOrbimed Advisors LLC Sells 391,302 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 15, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Beats Expectations By $0.23 EPSMay 14, 2025 | marketbeat.comEarnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock risesMay 14, 2025 | uk.investing.comIntegral Health Asset Management LLC Buys 519,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)May 14, 2025 | marketbeat.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comPositive Buy Rating for Lorundrostat Driven by Successful Trials and Future PotentialMay 13, 2025 | tipranks.comOptimistic Buy Rating for Mineralys Therapeutics Driven by Strategic Developments and Upcoming Data ReleasesMay 13, 2025 | tipranks.comMineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 13, 2025 | finance.yahoo.comMineralys Therapeutics stock rises on better-than-expected Q1 resultsMay 13, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCADL, AUPH, GYRE, and MLYS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.38 +0.04 (+0.43%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Candel Therapeutics NASDAQ:CADL$5.46 -0.01 (-0.18%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Gyre Therapeutics NASDAQ:GYRE$11.31 +0.94 (+9.06%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$16.13 -0.53 (-3.16%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
